Pyridoxamine - NephroGenex/Kowa

Drug Profile

Pyridoxamine - NephroGenex/Kowa

Alternative Names: BST-4001; K-163; K163SZ; Pyridorin; Pyridoxamine dihydrochloride

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioStratum
  • Developer Kowa; NephroGenex
  • Class Picolines; Small molecules
  • Mechanism of Action Advanced glycosylation end product inhibitors; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic nephropathies

Highest Development Phases

  • Phase II Schizophrenia
  • Suspended Diabetic nephropathies
  • No development reported Acute kidney injury

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for preclinical development in Acute kidney injury in USA (IV)
  • 23 Jan 2018 Phase-II clinical trials in Schizophrenia in Japan (unspecified) (Kowa pipeline, January 2018)
  • 20 Nov 2017 Kowa plans the phase II K-163-SZ trial for Schizophrenia in Japan (JapicCTI-173780)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top